January 30 (SeeNews) - LSE-listed biopharmaceutical company Amryt Pharma said on Tuesday it has signed an exclusive distribution agreement covering Romania and Bulgaria with Bucharest-based pharmaceutical services company Romastru Trading.
"Romastru's reach across Romania and Bulgaria means that we can now provide comprehensive access to Lojuxta for adult patients suffering from HoFH in these territories," Dr. Joe Wiley, chief executive officer (CEO) of Amryt Pharma, said in a statement.
Lojuxta is a treatment for homozygous familial hypercholesterolemia (HoFH). According to Amryt Pharma, there are approximately 30 patients with HoFH in Romania and Bulgaria combined.
"This is the fourth distribution agreement signed by Amryt in the last three months, and it broadens further the company's distribution footprint for Lojuxta in Central and Eastern Europe," the statement reads.
Amryt Pharma plans to complete further agreements across its in-licenced territories in Europe, Middle East and Africa throughout 2018, the company said.
Amryt Pharma is focused on developing treatments for people with rare and orphan diseases.
Romastru Trading is part of conglomerate Pharaon Healthcare Europe, which provides a wide range of services, including medical, marketing research, storage and distribution.